The nation of Zimbabwe has rejected a major American health deal worth 367 million US dollars (£272m) over five years due to Washington's insistence on confidential biological samples.
This rejection came to light following a official document dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the deal was "unbalanced".
A government representative later clarified that the US was requesting genetic material for research and commercial purposes while was unwilling to share the resulting advantages from any future vaccines.
"We will now turn to the challenging and unfortunate process of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged more talks to reach a deal acceptable to both sides so the nation's critical HIV treatment initiative can proceed.
Wider Background
This rejection comes after a comparable case in Kenya, where a high court blocked a related deal with the US following legal challenges were filed about the security of Kenyans' health data.
After returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing government-to-government deals to boost openness and accountability.
As per statements, 16 nations in Africa have to date agreed to these new agreements, representing over $18.3bn in new funding.
Details of the Declined Agreement
The funds for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment through US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its biological resources and data indefinitely, without any corresponding promise of access to any medical innovations – like new medicines or tests – that might be developed from that shared data," he stated.
"In essence, our nation would provide the basic resources for medical research with no certainty that the resulting innovations would be available to our people should a new pandemic emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were disrupting frameworks previously established through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This system is designed to guarantee that when a country contributes its data, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to further dialogue with our American counterparts on how future co-operation might be arranged in a manner that honours the sovereignty and dignity of both nations."
Medical Community Reaction
A leading public health body expressed it understood the official position, but recommended that negotiations need to persist since a large portion of the country's HIV programmes depended on international support.
"In cases where specific concerns arise, including those involving information security or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," it added.
The situation underscores the complex tensions between receiving vital international aid and protecting a country's data in an ever more interconnected world.